BLACK FRIDAY EARLY — BOGO 50% SITEWIDE

PE-22-28: Benefits, Mechanism, and What the Research Actually Shows

By the Ageless Humans editorial team · Updated 2026-11-14 · 6 min read

PE-22-28 is a synthetic seven-amino-acid peptide derived from spadin, a naturally occurring fragment of the sortilin protein. Researchers have studied it mainly in rodents for its ability to block the TREK-1 potassium channel, a target linked to mood regulation, new neuron growth, and neuroprotection. The early animal data is interesting, but no published human clinical trials exist, and it is not an approved drug or a dietary supplement.

What Is PE-22-28?

PE-22-28 is a short, lab-made peptide built from amino acids 22 through 28 of a larger natural molecule called the sortilin propeptide (PE). The name describes it exactly: PE for propeptide, and 22-28 for the stretch of amino acids it copies.

Here is the family tree in plain terms:

  • Sortilin is a receptor protein found throughout the body, including the brain.
  • When the body makes sortilin, it trims off a 44-amino-acid piece called the propeptide (PE).
  • A 17-amino-acid fragment of that propeptide, named spadin, was found to interact with a potassium channel called TREK-1.
  • PE-22-28 is a shortened, seven-amino-acid version of spadin that researchers designed to keep the useful activity in a smaller molecule.

If you are new to this category, our guide on what peptides are explains how short chains of amino acids act as signaling molecules. For a compound-level summary, see our PE-22-28 peptide overview.

How PE-22-28 Works: The TREK-1 Mechanism

PE-22-28's main studied mechanism is blocking TREK-1, a potassium channel that helps keep neurons in a quieter, less excitable state. When TREK-1 is open, potassium flows out of the cell and the neuron becomes less likely to fire. Blocking it tips the balance toward more activity.

Why does that matter? Researchers became interested in TREK-1 after earlier work in mice bred without the channel. Those animals behaved in ways that, in standard lab tests, looked resistant to stress-induced, depression-like behavior. That made TREK-1 a candidate target, and spadin, followed by PE-22-28, became tools for testing whether blocking it pharmacologically produces similar effects.

In animal studies, TREK-1 blockade by these peptides has been associated with downstream changes researchers care about:

  • Increased signaling through pathways tied to brain plasticity, including markers such as BDNF and CREB activity.
  • Hippocampal neurogenesis, meaning the formation of new neurons in a memory- and mood-relevant brain region.
  • Synaptogenesis, meaning the formation of new connections between neurons.

The mechanism is the most solid part of the PE-22-28 story. Effects in a lab animal, however, do not automatically translate into effects in a person.

What PE-22-28 Has Been Studied For

PE-22-28 has been studied mainly in rodents for mood-related behavior, brain plasticity, and neuroprotection. Nearly all of the published work comes from a small number of academic research groups, much of it in France, that also characterized spadin.

1. Mood-related behavior in animal models. This is the core research focus. In standard rodent behavior tests, PE-22-28 and related spadin analogs produced responses researchers interpret as antidepressant-like. A recurring theme in this work is speed: the effects appeared after a shorter treatment period in animals than researchers typically see with conventional approaches studied in the same models.

2. Neurogenesis and synaptic plasticity. Researchers measured new neuron formation and synaptic markers in treated animals. These findings matter because many scientists view reduced plasticity as one biological thread connecting stress, mood, and cognition.

3. Neuroprotection in injury models. Spadin-family peptides have also been studied in rodent models of ischemia, where blood flow to the brain is interrupted. Some of this work suggests that blocking TREK-1 may support neuron survival and recovery under those lab conditions.

4. Improved drug-like properties. Part of the reason PE-22-28 exists is practical. Researchers reported that the shortened peptide and some modified versions held up longer in the body than full-length spadin while keeping comparable activity in their models. That is a pharmacology finding, not a benefit to the user.

Claimed Benefits vs. Evidence: An Honest Scorecard

The honest answer: PE-22-28's benefits are reported in animal research only. Claims you see online about human mood, focus, or memory go beyond what the published evidence shows. Here is how the main claims stack up.

  • Blocks TREK-1: Supported by lab and animal data. This is the best-established finding.
  • Mood support: Studied in rodent behavior models with consistent-looking results from a small research base. No published human trials.
  • Faster onset than conventional approaches: Observed in animal models. Untested in people.
  • New neuron growth and plasticity: Reported in rodents. Unknown in humans.
  • Cognitive enhancement or nootropic effects: Mostly anecdotal. Not a primary endpoint in the core research.
  • Neuroprotection: Studied in rodent injury models. Early-stage.

Two cautions round out the picture. First, the research comes from a narrow group of labs, and broad independent replication is limited. Second, rodent behavior tests are useful screening tools, but they are imperfect stand-ins for human experience. Many compounds that look promising in mice never show the same effects in people.

Safety, Side Effects, and What Isn't Known

No one can say PE-22-28 is safe for humans, because it has not been formally tested in humans. Animal studies reported that spadin-family peptides did not produce some of the side effects researchers worried about with TREK-1 blockade. Animal safety data is still not human safety data.

The biggest open questions:

  • Long-term effects. TREK-1 is found in the heart, gut, and other tissues as well as the brain. The long-term consequences of blocking it in people are not established.
  • Interactions. There is no human data on how PE-22-28 interacts with medications, especially those that affect mood or brain chemistry.
  • Product quality. PE-22-28 is sold online as a research chemical. These products are not dietary supplements and are not regulated as such. Purity, identity, sterility, and actual content can vary widely, and many sellers provide no meaningful verification.

Because there are no established human dosing guidelines, we do not discuss doses. Anyone dealing with mood concerns should talk with a qualified healthcare provider. That conversation matters more than any experimental compound.

PE-22-28 vs. Other Peptide Categories

PE-22-28 is a synthetic, single-target research peptide. That separates it from bioregulators and from the recovery-focused peptides people often group it with. It helps to know which bucket a compound belongs in.

  • Synthetic receptor-targeted peptides (like PE-22-28): Designed to act on one specific molecular target. They are powerful research tools, usually with narrow and early evidence.
  • Bioregulator peptides: Very short peptides studied for supporting tissue-specific gene expression and cellular function. Our explainer on what bioregulators are covers how that research tradition differs.
  • Recovery-oriented peptides (like BPC-157 and TB-500): Studied mainly for tissue repair and recovery signaling rather than brain channels.

These categories are not interchangeable. A peptide's value depends on its target, its evidence base, and whether it is available in a form that is legally sold and quality-controlled.

Should You Pay Attention to PE-22-28?

PE-22-28 is worth following as science, and caution is the right response to it as a consumer product. The TREK-1 research is a legitimate and interesting line of neuroscience. It points to a new way of thinking about mood biology and brain plasticity.

The practical next step for the field is well-designed human research. Until that exists, the most useful thing you can do is keep separate what has been shown (a clear mechanism plus encouraging animal data) from what is being marketed (human benefits that have not been tested).

In the meantime, the inputs with the strongest human evidence for brain and mood resilience are not exotic: consistent sleep, regular exercise, sunlight, social connection, and a nutrient-dense diet. They are less exciting than a novel peptide, and far better supported.

Related reading & products

Frequently asked questions

What is PE-22-28?+

PE-22-28 is a synthetic seven-amino-acid peptide based on spadin, a natural fragment of the sortilin propeptide. It was designed as a shorter, more stable version of spadin that blocks the TREK-1 potassium channel. It is a research compound, not an approved drug or a dietary supplement.

What are the benefits of PE-22-28?+

In rodent studies, PE-22-28 has been associated with antidepressant-like behavior, increased hippocampal neurogenesis, more synaptic plasticity, and neuroprotective effects in injury models. These findings come from animal research only. No published human clinical trials confirm any benefit in people.

How does PE-22-28 work?+

PE-22-28 blocks TREK-1, a potassium channel that normally keeps neurons in a less excitable state. In animal studies, blocking TREK-1 was linked to increased plasticity-related signaling, including BDNF and CREB activity, along with new neuron formation. This mechanism is the best-characterized part of the research.

Has PE-22-28 been tested in humans?+

No published human clinical trials of PE-22-28 exist. The research base is preclinical, made up of cell and animal studies, and comes mostly from a small number of academic labs. Its human safety, effectiveness, and long-term effects are unknown.

Is PE-22-28 a dietary supplement?+

No. PE-22-28 is not a dietary supplement and is not an FDA-approved drug. It is usually sold online as a research chemical, and those products are not regulated as supplements. Quality, purity, and identity can vary widely between sellers.

Is PE-22-28 the same as a bioregulator peptide?+

No. PE-22-28 is a synthetic peptide designed to act on one target, the TREK-1 channel. Bioregulators are a separate class of very short peptides studied for supporting tissue-specific cellular function. Their mechanisms, research histories, and uses are different.

Keep reading